Search - tctmd.com

Displaying 61 - 80 of 2429

Sort: Relevancy | Date

News Daily News

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

Yael L. Maxwell

June 09, 2025

News Daily News

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Todd Neale

June 06, 2025

News Daily News

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Michael O'Riordan

June 04, 2025

News Conference News EuroPCR 2025

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Yael L. Maxwell

June 02, 2025

News Conference News EuroPCR 2025

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

L.A. McKeown

May 30, 2025

News Conference News EuroPCR 2025

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Michael O'Riordan

May 29, 2025

News Conference News EuroPCR 2025

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Yael L. Maxwell

May 23, 2025

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

News Conference News European Congress on Obesity 2025

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

Michael O'Riordan

May 14, 2025

News Daily News

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Caitlin E. Cox

May 06, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Conference News ACC 2025

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

Michael O'Riordan

April 02, 2025

News Conference News ACC 2025

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Michael O'Riordan

March 29, 2025

Presentation ACC 2025

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Presenter: Darren K. McGuire

March 29, 2025

Presentation ACC 2025

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Presenter: Isabelle Mahé

March 29, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Daily News

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

Michael O'Riordan

March 26, 2025

News Daily News

ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care

Caitlin E. Cox

March 19, 2025

Advertisement

Fewer MACCE With P2Y12 Inhibitor vs Aspirin Monotherapy Over 5 Years

JACC Dedicates Issue to Deep Dive on Latest ACS Guidelines

Inclisiran Plus Usual Care Improves LDL Control in ACS: VICTORION-INCEPTION

Short DAPT All That’s Needed With Contemporary DES: HOST-IDEA at 3 Years

Short DAPT Safe in ACS With No Ischemic Penalty: 4D-ACS

‘Quick and Sustained’ Bumps in HR and BP When Beta-blockers Stopped Post-MI

Short DAPT in High-Bleeding-Risk Patients Reduces Recurrent Events: MASTER DAPT

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

SELECT: Semaglutide’s Impact on CVD Events Emerges Quickly

AHA/ACC Issue New Performance, Quality Measures for Chronic Coronary Disease

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

RIVAWAR: Rivaroxaban as Safe and Effective as Warfarin for LV Thrombus in MI

SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes

Oral Semaglutide Reduces Cardiovascular Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the SOUL Randomized Trial

Extended Anticoagulant Treatment With A Reduced Versus Full Dose Apixaban In Patients With Cancer-associated Venous Thromboembolism: The API-CAT Study

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

ISCHEMIA: No Clinical Event Reduction With Invasive Strategy in CTO Patients

ACC Releases ‘Concise Clinical Guidance’ for Cardiogenic Shock Care

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content